Tag : ENDOMETRIAL CANCER

Dostarlimab in conjunction with carboplatin-paclitaxel (CP) has previously been shown to significantly improve progression-free survival (PFS) and overall survival (OS) outcomes compared with CP alone in patients with primary advanced or recurrent endometrial cancer (EC).1 This has led to its approval in the first line for EC patients in the mismatch repair deficient (dMMR) microsatellite instability-high (MSI-H) population. However, more data are required to describe the health-related quality of life (HRQoL) of this immunotherapy CP combination over extended periods.

Progression-free survival (PFS) is often utilized as an indicator of the overall survival (OS) of patients with endometrial cancer (EC) to facilitate regulatory approval for novel medical treatments. Nevertheless, its role as a surrogate marker for the survival outcomes of EC patients remains controversial among medical practitioners, with some questioning its reliability and suggesting its inability to reflect the eventual endpoint of the disease. To investigate PFS surrogacy on OS among patients with recurrent and advanced EC, the European Organization For Research and Treatment of Cancer Young Gynaecologic Cancer Group (EORTC-YGCG) conducted a systematic review of randomized phase 2 and 3 clinical trials in advanced/recurrent EC. During ESGO 2024 Congress,  Dr. Ramon Yarza from the Royal Marsden Hospital, London, the United Kingdom, shared the findings of this review.

Since the publication of the last International Federation of Gynecology and Obstetrics (FIGO) staging system for endometrial cancer in 2009, a substantial amount of new evidence has been acquired regarding tumor biology and the prognostic significance of molecular subgroups. The Cancer Genome Atla